Study design (if review, criteria of inclusion for studies)
phase III multicenter vaccine trial using the Pseudomonas aeruginosa 5142/1210-Flagella Vaccine IMMUNO was initiated. placebo-controlled, randomized and double-blind design.
Participants
400 CF patients without P. aeruginosa lung infection m 16 CF centers in Germany, France and Italy.